Multiple Sclerosis Therapeutics Market in Europe Is Driven By High Prevalence of Multiple Sclerosis in the Region

Multiple sclerosis is a long-term disease that attacks the central nervous system, affecting the brain, spinal cord, and optic nerves. It can lead to a wide range of symptoms throughout the body. There are four types of multiple sclerosis: clinically isolated syndrome, relapse-remitting multiple sclerosis, primary progressive multiple sclerosis, and secondary progressive multiple sclerosis. Around 80 percent of people with multiple sclerosis report having fatigue. Other symptoms include, acute or chronic pain, tremor, and cognitive issues involving concentration, memory, and word-finding difficulty. Although there is not yet a cure for multiple sclerosis, there are many effective medications to help you manage the disease.

The PDF for the study can be requested using the following link: https://www.coherentmarketinsights.com/insight/request-pdf/1310

According to a study by National MS Society, published in February 2019, in the journal Neurology, in 2017, nearly 1 million adults were living with multiple sclerosis in the U.S. Such high prevalence is expected to aid in growth of the multiple sclerosis therapeutics market.

Treatment for multiple sclerosis may include, chemotherapy, anti-inflammatory drugs, monoclonal antibodies, immunosuppressive drugs, and steroids. In September 2019, F. Hoffmann-La Roche Ltd., a major player in the multiple sclerosis therapeutics market, presented OCREVUS (ocrelizumab) biomarker data that highlights new insights into the biology of multiple sclerosis at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in Stockholm, Sweden.

The multiple sclerosis therapeutics market in Europe is driven by high prevalence of multiple sclerosis in the region. According to data from (updated November 2018), the Multiple Sclerosis Trust, the prevalence of MS in England is around 90,500 or 164 per 100,000 and about 3,200 or 175 per 100,000 in Northern Ireland.

Key Players

The major players operating in the global multiple sclerosis therapeutics market include Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co., Inc., and AbbVie, Inc.

Multiple sclerosis treatment is often used to slow the progression of the disease and relieve symptoms. Currently, there are various approved drugs to treat multiple sclerosis in the multiple sclerosis therapeutics market that include, Fingolimod (Gilenya), Dimethyl fumarate (Tecfidera), Diroximel fumarate (Vumerity), Teriflunomide (Aubagio), Siponimod (Mayzent), and Cladribine (Mavenclad). IV steroids are sometimes used to reduce and control the symptoms of an acute attack of multiple sclerosis. Players in the multiple sclerosis therapeutics market can also focus on autologous hematopoietic stem cell transplant as a potential option. In November 2020, the National MS Society stated that autologous hematopoietic stem cell transplant represents “a useful treatment option” for patients with relapsing multiple sclerosis who experience breakthrough disease activity despite disease-modifying therapy.

Buy Now with Discount for Premium Report : https://www.coherentmarketinsights.com/promo/buynow/1310

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.